Pfizer seeks emergency use of COVID-19 vaccine in India

Édité par Ed Newman
2020-12-07 10:24:09

Pinterest
Telegram
Linkedin
WhatsApp

Vials with COVID-19 Vaccine stickers attached and syringes with the logo of US pharmaceutical company Pfizer and German partner BioNTech. (Photo: AFP)

New Delhi, December 7 (RHC)-- Pfizer India has become the first pharmaceutical firm to seek an emergency use authorization for its COVID-19 vaccine in India, which has the second highest number of coronavirus infections.

“Pfizer India has submitted an application to the DCGI seeking emergency use authorization (EUA) for its COVID-19 vaccine in India,” Indian media reported, referring to the Drugs Controller General of India (DCGI).  “Pfizer India has sought permission for emergency usage authorization of its COVID-19 from DGCI to import and market,” an official was quoted as saying.

Pfizer India is a subsidiary of the parent company Pfizer Inc., an American multinational pharmaceutical corporation based in New York.

The United Kingdom on Wednesday became the first country to approve the Pfizer/BioNTech vaccine against COVID-19, with the UK regulator Medicines and Healthcare products Regulatory Agency (MHRA) granting a temporary authorization for its emergency use.

India has reported more 9.57 million COVID–19 cases, behind only the United States, with nearly 140,000 deaths.


 



Commentaires


Laissez un commentaire
Tous les champs sont requis
Votre commentaire ne sera pas publié
captcha challenge
up